Cart
sales@molnova.com
CDK9-IN-7
CAS No. 2369981-71-3
CDK9-IN-7( —— )
Catalog No. M32835 CAS No. 2369981-71-3
CDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 228 | In Stock |
|
| 5MG | 208 | In Stock |
|
| 10MG | 303 | In Stock |
|
| 25MG | 457 | In Stock |
|
| 50MG | 617 | In Stock |
|
| 100MG | 827 | In Stock |
|
| 200MG | 1097 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCDK9-IN-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionCDK9-IN-7 is a highly selective and orally active CDK9/cyclin T inhibitor (IC50: 11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD: 148 nM; CDK6/cyclinD: 145 nM).
-
DescriptionCDK9-IN-7 (compound 21e) is a selective, highly potent, and orally active CDK9/cyclin T inhibitor (IC50=11 nM), which exhibits more potent over other CDKs (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM). CDK9-IN-7 shows antitumor activity without obvious toxicity. CDK9-IN-7 induces NSCLC cell apoptosis, arrests the cell cycle in the G2 phase, and suppresses the stemness properties of NSCLC.
-
In VitroCDK9-IN-7 displays exceptional potency against NSCLC cell lines, especial A549 and H1299 with IC50 values less than 0.5 μM. In the drug-resistant NSCLC cell line H1975, CDK9-IN-7 also exhibits good inhibition potency with an IC50 value of 0.837 μM.
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2369981-71-3
-
Formula Weight547.71
-
Molecular FormulaC29H37N7O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 62.5 mg/mL (114.11 mM; Ultrasonic )
-
SMILESC(N(C)C)(=O)C=1N(C=2C(C1)=CN=C(NC3=CC=C(NC(CCCCCCCN=C=S)=O)C=C3)N2)C4CCCC4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wang X, et al. Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer. Eur J Med Chem. 2019 Jul 25;181:111535.?
molnova catalog
related products
-
CDK9-IN-15
CDK9-IN-15 is a potent small molecule CDK9 inhibitor, which can block the phosphorylation of positive transcription elongation factor b (P-TEFb) on the C-terminal region of RNA Poly-II by degradation and inhibition of CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing apoptosis of tumor cells.
-
AZ5576
AZ5576, a potent and highly selective CDK9 inhibitor, can be used for research on Hematological Malignancy .
-
CDK12-IN-3
CDK12-IN-3 is a selective and potent CDK12 inhibitor with anti-tumor activity, which can be used to study malignant tumors.
